TY  - JOUR

T1  - Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA).

JO  - Journal of Clinical Oncology

PY  - 2013/02/20

AU  - Vogelzang NJ

AU  - Parker C

AU  - Nilsson S

AU  - Coleman RE

AU  - O'Bryan-Tear CG

AU  - Shan M

AU  - Sartor AO

ED  - 

DO  - DOI: 10.1200/jco.2013.31.6_suppl.11

PB  - American Society of Clinical Oncology (ASCO)

VL  - 31

IS  - 6_suppl

SP  - 11

EP  - 11

Y2  - 2025/10/10

ER  -